Recursion and Exscientia Merge, Create New Drug Discovery Company
US-headquartered biotech firm Recursion has announced that it will acquire UK-based pharmatech Exscientia in an all-stock deal. The transaction, which is expected to close in early 2025, would provide the combined entity with approximately $850 million in cash to fund its operations for the next three years. Reuters reported that Recursion will pay $688 million for the acquisition of Exscientia.
